Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

NCT05322096 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Prader-Willi Syndrome

Interventions

DRUG: RGH-706
DRUG: Placebo

Sponsor

Gedeon Richter Plc.